Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Non-Randomized, Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

NCT07623642 is registered in ClinicalTrials.gov with GV20 Therapeutics as lead sponsor.

NCT NCT07623642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07623642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Non-Randomized, Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors
Lead sponsor
GV20 Therapeutics
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 2, 2026
Completion date
August 15, 2029
Enrollment
227 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, cholangiocarcinoma, colorectal neoplasms, esophageal squamous cell carcinoma, gallbladder neoplasms, pancreatic ductal adenocarcinoma, prostatic neoplasms, small cell lung carcinoma, squamous cell carcinoma of head and neck, triple negative breast neoplasms, uterine cervical neoplasms